SCHEMBL25094378

SCHEMBL25094378

CC(C)(C)c1ccc(-c2ccccc2CNC2CC2)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ KMT2A Q03164 5/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ LMNA P02545 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ ALOX12 P18054 1/20 0.38
▸ LTA4H P09960 1/20 0.36
▸ RAB9A P51151 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ EP300 Q09472 1/20 0.34
▸ BCHE P06276 1/20 0.33
▸ ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25094367 0.95 CYP2D6 (0.40) SLC6A2SLC6A4SLC6A3KMT2AMEN1
SCHEMBL24401325 0.81 LTA4H (0.55) SLC6A2SLC6A4SLC6A3LTA4HCYP2D6
SCHEMBL15525097 0.80 SLC6A2 (0.42) SLC6A2SLC6A4SLC6A3KMT2AMEN1
SCHEMBL25094380 0.78 SOS1 (0.40) SLC6A2SLC6A4SLC6A3GAALTA4H
SCHEMBL25094331 0.76 PKM (0.43) KMT2AMEN1L3MBTL1LTA4HBCHE
SCHEMBL25094332 0.75 KRAS (0.44) LTA4HBCHEACHEKDM4E
SCHEMBL25094675 0.74 PDCD1 (0.40) KMT2ALTA4HPDCD1CD274
SCHEMBL23344698 0.74 DPP4 (0.44) LTA4HCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL17549761 0.74 KMT2A (0.46) SLC6A2SLC6A4SLC6A3KMT2AMEN1
SCHEMBL15525099 0.74 LTA4H (0.62) SLC6A2SLC6A4SLC6A3KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KUMQUAT BIOSCIENCES INC. (US) 2023-05-16 — — US disclosed
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KUMQUAT BIOSCIENCES INC. (US) 2023-05-16 — — US disclosed
US-20230064360-A1 HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2023-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KRAS, NRAS, BRAF SLC6A2 3927/4885SLC6A4 3795/4885SLC6A3 3345/4885
US-20230064360-A1 HETEROCYCLES AND USES THEREOF KRAS, HRAS, TP53 SLC6A2 4126/4885SLC6A4 3920/4885SLC6A3 3535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback